Tuesday, 24 October 2017
Latest news
Main » Earnings Analysis Of Valeant Pharmaceuticals International, Inc. (VRX)

Earnings Analysis Of Valeant Pharmaceuticals International, Inc. (VRX)

12 October 2017

Creative Planning holds 0% or 8,086 shares. The Regal Investment Advisors Llc holds 37,463 shares with $2.91 million value, down from 41,954 last quarter. Sysco Corp now has $28.21 billion valuation. (CMI) stock brought in a $0.4 rise to $172.11. Its up 35.52% from 1.22M shares previously. It has underperformed by 5.47% the S&P500. Canaccord Genuity maintained the shares of VRX in report on Wednesday, March 16 with "Hold" rating. It is 0.00% or $0 reaching $0.71 per share. About 10,692 shares traded. It has underperformed by 16.70% the S&P500.

The next earnings announcement is expected on Nov 07, 2017. During the same period in the previous year, the firm posted ($0.88) earnings per share. SYY's profit will be $381.64 million for 18.48 P/E if the $0.73 EPS becomes a reality. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.87 by $1.93. When investing in a volatile security, the risk of success is increased just as much as the risk of failure. Its up 0.08, from 0.79 in 2017Q1. 84 funds opened positions while 258 raised stakes. The share price has already crossed its 20 days moving average, floating at a distance of 2.29% and sits 0.55% higher versus its 50 days moving average. Jane Street Group Inc Ltd Company has 728,872 shares for 0.04% of their portfolio. Amica Mutual Ins owns 29,544 shares. The company moved in the past week with shift of 0.91%. Jane Street Grp Limited Liability invested in 728,872 shares. Capital One Association reported 0.43% in SYSCO Corporation (NYSE:SYY). First Trust Advsrs Ltd Partnership accumulated 256,500 shares. The Gramercy Funds Management Llc holds 11,800 shares with $204,000 value, down from 82,500 last quarter. 376,637 are owned by Dana Incorporated. For the past 5 years, the company's revenue has grown -5.4%, while the company's earnings per share has grown -25.3%. The insider Shurts Wayne sold $862,914. Lowe's Companies Inc. had 56 analyst reports since August 19, 2015 according to SRatingsIntel. The mean target price as estimated by the analysts for the company has been recorded at $00.00. The rating was maintained by Cantor Fitzgerald on Monday, September 25 with "Buy". Stifel Nicolaus has "Buy" rating and $3500 target. (CPHI) stock confirmed the flow of 4.18% with the final price of $0.18. The company was maintained on Wednesday, April 12 by Guggenheim. The stock has "Underperform" rating by Mizuho on Monday, February 27. On Friday, October 9 the stock rating was initiated by Mizuho with "Neutral". JP Morgan has "Neutral" rating and $57 target.

Since May 11, 2017, it had 1 buy, and 0 sales for $278,000 activity.

In other news, Director Schutter Richard U. De acquired 10,000 shares of the business's stock in a transaction on Monday, August 21st.

Hap Trading Llc decreased Micron Technology Inc (NASDAQ:MU) stake by 739,219 shares to 94,981 valued at $2.84M in 2017Q2. It also reduced its holding in Wayfair Inc (NYSE:W) by 167,700 shares in the quarter, leaving it with 1.15M shares, and cut its stake in Twitter Inc (NYSE:TWTR). Dimensional Fund Advsrs Lp has invested 0.01% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Therefore 22% are positive.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) traded down 1.08% during trading on Thursday, hitting $12.79. Jefferies maintained it with "Buy" rating and $18.0 target in Wednesday, September 13 report. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned "Sector Outperform" rating by Scotia Capital on Friday, July 24. The company has market cap of $2.09 billion. Rodman & Renshaw downgraded Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Thursday, November 10 to "Neutral" rating. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Overweight" rating given on Wednesday, August 17 by Morgan Stanley. The rating was maintained by Keefe Bruyette & Woods on Tuesday, October 3 with "Hold". The stock has "Equal-Weight" rating by Stephens on Thursday, May 26.

08/10/2017 - Valeant Pharmaceuticals International, Inc. had its "market perform" rating reiterated by analysts at BMO Capital Markets.

Investors sentiment decreased to 1.08 in Q2 2017. Its down 0.16, from 1.24 in 2017Q1. It is negative, as 53 investors sold VRX shares while 76 reduced holdings.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Meiji Yasuda Asset Mgmt holds 20,443 shares or 0.16% of its portfolio. Tyrus Cap Sam holds 0.17% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 127,000 shares. Sg Americas Secs Limited Liability reported 0% stake. Armstrong Henry H Assoc Inc has invested 0.31% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

06/12/2017 - Valeant Pharmaceuticals International, Inc. had its "buy" rating reiterated by analysts at CFRA Research. The Texas-based Academy Capital Management Inc Tx has invested 3.02% in the stock. (NYSE:VRX) slightly down of -0.28% and Altaba Inc. Central Securities Corp owns 700,000 shares or 1.99% of their USA portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.